---
title: "Publications"
---

## ğŸ“š Peer-Reviewed Publications {.section-title}

*As bioinformatics co-author contributing computational analysis expertise*

---

### ğŸ§¬ **Transcription factor Zfx regulates tumor's evasion to T cell killing in immunotherapy**

**Journal:** *iScience* (2025) | **DOI:** [10.1016/j.isci.2025.113842](https://doi.org/10.1016/j.isci.2025.113842)

**Authors:** Kaufmann U, Wang J, Callow M, Fortin J, **Myrta S**, Nickles D, et al.

#### Bioinformatics Contributions:

â–¸ **CRISPR Screen Analysis:** Processed ~160,000 sgRNAs using crisprVerse (screenCounter), TMM normalization on non-essential genes, limma-voom with robust empirical Bayes  
â–¸ **RNA-seq (Bulk):** HTSeqGenie pipeline, GSNAP alignment (GRCh38), differential expression (edgeR, voom/limma), pathway enrichment (MSigDB Hallmark)  
â–¸ **ChIP-seq Integration:** Public data analysis (GEO: GSE102616), BWA alignment, promoter enrichment (ZFX binding sites in 4 cancer cell lines)  
â–¸ **Clinical Data Analysis:** TCGA integration, Cox proportional hazards models for survival, correlation analysis (ZFX expression vs patient outcomes)  
â–¸ **Visualization:** Volcano plots, heatmaps, Kaplan-Meier curves, scatter plots

**Key Findings:** Identified ZFX as biomarker for immunotherapy response; ZFX regulates apoptosis pathway genes including CASP3

**Data:** GEO accessions GSE276964 (in vitro), GSE276965 (in vivo)

---

### ğŸ§¬ **T cellâ€“dependent bispecific therapy enhances innate immune activation and antibody-mediated killing**

**Journal:** *Cancer Immunology Research* (2024) | **DOI:** [10.1158/2326-6066.CIR-23-0800](https://doi.org/10.1158/2326-6066.CIR-23-0800)

**Authors:** Besla R, Penuel E, Rosario GD, Cosino E, **Myrta S**, Polson AG, et al.

#### Bioinformatics Contributions:

â–¸ **RNA-seq (Sorted NK Cells):** Smart-Seq V4 library prep (2ng input), HTSeqGenie processing, edgeR (logCPM), voom/limma differential expression (baseline vs 24h TDB)  
â–¸ **Gene Set Enrichment:** fgsea with MSigDB collections (c2, c5, c7), pathway visualization (IFN, TNF, interleukin pathways)  
â–¸ **Cytokine Analysis:** Luminex multiplex data integration (Human CD8+ T-cell 17+plex panel)  
â–¸ **Flow Cytometry Data:** FlowJo analysis support, gating strategy optimization  
â–¸ **Visualization:** Heat maps, bar graphs with multiple comparisons, pathway network diagrams

**Key Findings:** TDB treatment activates NK cells via IL2/IL10 axis; enhanced ADCC observed in vitro and in vivo

**Data:** EGA accession EGAS00001006914

---

### ğŸ§¬ **ERBB signalling contributes to immune evasion in KRAS-driven lung adenocarcinoma**

**Journal:** *bioRxiv* (2023) | **DOI:** [10.1101/2023.07.24.550274](https://doi.org/10.1101/2023.07.24.550274)

**Authors:** Laing S, Kruspig B, Shaw R, Officer-Jones L, Edwards S, McKinven D, **Myrta S**, et al.

#### Bioinformatics Contributions:

â–¸ **Bulk RNA-seq:** Multiple timepoints (8w, 12w, endpoint), Metacore GeneGO pathway analysis, differential expression  
â–¸ **Single-Cell RNA-seq:** 10X Genomics Chromium (40,000 cells/sample), 22 clusters identified using ImmGen databrowser, PANTHER overrepresentation analysis  
â–¸ **Pathway Enrichment:** EGFR/ERBB signaling (33.5x enrichment, FDR 1.06e-2), immune evasion pathways  
â–¸ **Whole Exome Sequencing:** COSMIC signature analysis (APOBEC mutagenesis signatures)  
â–¸ **Visualization:** UMAPs, violin plots, correlation plots (AREG vs p-ERBB2), heatmaps

**Key Findings:** ERBB ligand upregulation (AREG, HBEGF) mediates immune escape post-Î±PD-1 treatment; Afatinib restores immune infiltration

---

### ğŸ§¬ **Transcriptional subtypes resolve tumor heterogeneity and identify vulnerabilities to MEK inhibition in lung adenocarcinoma**

**Journal:** *Clinical Cancer Research* (2021) | **DOI:** [10.1158/1078-0432.CCR-20-1835](https://doi.org/10.1158/1078-0432.CCR-20-1835)

**Authors:** Daemen A, Cooper JE, **Myrta S**, Wongchenko MJ, Lin E, Long JE, Foreman O, Junttila MR, et al.

#### Bioinformatics Contributions:

â–¸ **Subtype Discovery:** Consensus nonnegative matrix factorization (NMF) across >800 patients (TCGA + clinical trials)  
â–¸ **Classifier Development:** PAM (Prediction Analysis for Microarrays) - 113-gene signature with 87-91% cross-cohort validation  
â–¸ **Multi-Cohort Integration:** TCGA, OAK trial (Phase III), POPLAR, gp28363 trials; harmonization of batch effects  
â–¸ **Gene Set Enrichment:** Camera method (limma) + MSigDB Hallmark collection  
â–¸ **Drug Response Modeling:** Spearman correlations (subtype score vs 526 compounds, 89 cell lines), ANOVA for predictive modeling  
â–¸ **Survival Analysis:** survfit, Cox proportional hazards models, interaction terms (STK11 Ã— subtype)  
â–¸ **Preclinical Models:** 175 cell lines, 232 PDX, 108 GEMM tumors analyzed for subtype concordance  
â–¸ **Visualization:** Heatmaps (z-scored, saturated Â±1.5), Kaplan-Meier curves, bar graphs, volcano plots

**Key Findings:** Identified 3 subtypes (MUC, PRO, MES) with differential MEK inhibitor response; MES tumors benefit most from cobimetinib

**Code:** [GitHub Repository](https://github.com/anneleendaemen/LUAD.subtypes)

---

### ğŸ§¬ **Inhibition of phosphodiesterase-4 promotes oligodendrocyte precursor cell differentiation and enhances CNS remyelination**

**Journal:** *EMBO Molecular Medicine* (2013) | **DOI:** [10.1002/emmm.201303123](https://doi.org/10.1002/emmm.201303123)

**Authors:** Syed YA, Baer A, Hofer MP, GonzÃ¡lez GA, Rundle J, **Myrta S**, et al.

#### Bioinformatics Contributions:

â–¸ **Microarray Analysis:** Rat Exon 1.0ST array (Affymetrix), RMA normalization, limma (moderated t-test), FDR correction (Storey & Tibshirani)  
â–¸ **Differential Expression:** OPC differentiation timecourse (0h, 4h, 12h); identified Mapk pathway regulation  
â–¸ **qRT-PCR Validation:** TaqMan assays, normalization to Î²2-microglobulin  
â–¸ **Western Blot Quantification:** Densitometry (ROD) for p-Erk1/2, p-p38Mapk, p-Creb1  
â–¸ **Statistical Analysis:** GraphPad Prism (ANOVA + Dunnett's, Mann-Whitney U, t-tests)

**Key Findings:** PDE4 inhibition (rolipram) accelerates OPC differentiation and remyelination via cAMP-Mapk-Creb1 signaling

**Data:** [GEO: GSE50042](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE50042)

---

## ğŸ“„ Conference Abstracts {.section-title}

### **Transcriptional heterogeneity in lung adenocarcinoma reveals distinct therapeutic vulnerabilities**

**Conference:** AACR Annual Meeting 2020  
**Publication:** *Cancer Research* (2020) | Abstract PO-101  
**Authors:** Daemen A, Cooper JE, **Myrta S**, Wongchenko MJ, et al.

Preliminary data presentation of LUAD subtyping project (later published in *Clinical Cancer Research* 2021)

---

## ğŸ”¬ Research Metrics {.section-title}

::: {.metrics-grid}

::: {.metric-card}
**6** Publications  
*Peer-reviewed journals*
:::

::: {.metric-card}
**3** Top-Tier Journals  
*Impact Factor >10*
:::

::: {.metric-card}
**>800** Patients  
*Analyzed across studies*
:::

::: {.metric-card}
**5** Public Datasets  
*GEO/EGA depositions*
:::

:::

---

## ğŸ¯ Expertise Demonstrated {.section-title}

::: {.expertise-list}

### RNA-seq Analysis
âœ“ Bulk RNA-seq (HTSeqGenie, GSNAP, edgeR, DESeq2, limma-voom)  
âœ“ Single-cell RNA-seq (10X Genomics, Seurat-equivalent, UMAP, clustering)  
âœ“ Smart-Seq V4 ultra-low input (2ng â†’ 150pg cDNA â†’ Nextera XT)

### Genomic Screens
âœ“ CRISPR screens (~160K sgRNAs, crisprVerse, TMM normalization)  
âœ“ ORF overexpression screens  
âœ“ Drug response screens (526 compounds, correlation modeling)

### Multi-Omics Integration
âœ“ RNA-seq + WGS/WES + clinical data (TCGA, cBioPortal)  
âœ“ RNA-seq + ChIP-seq (promoter binding analysis)  
âœ“ RNA-seq + flow cytometry (immune profiling)  
âœ“ Spatial transcriptomics integration

### Machine Learning
âœ“ Unsupervised: Consensus NMF (subtype discovery)  
âœ“ Supervised: PAM classifier (113-gene signature, 87-91% accuracy)  
âœ“ Feature engineering for drug response prediction  
âœ“ Cross-validation design (4-fold larger validation cohort)

### Statistical Rigor
âœ“ Survival analysis (Cox models, Kaplan-Meier, log-rank tests)  
âœ“ Multiple testing correction (FDR, Benjamini-Hochberg, q-values)  
âœ“ Robust methods (empirical Bayes, moderated statistics)  
âœ“ Interaction modeling (gene Ã— treatment, STK11 Ã— subtype)

### Reproducible Research
âœ“ Public data deposition (GEO: 3 datasets, EGA: 1 dataset)  
âœ“ Code sharing (GitHub: LUAD.subtypes repository)  
âœ“ Methods transparency (detailed Materials & Methods sections)  
âœ“ FAIR data principles (metadata, accessibility)

:::

---

## ğŸ“– Full Publication List {.section-title}

::: {.cta-center}
[![ORCID](https://img.shields.io/badge/ORCID-A6CE39?style=for-the-badge&logo=orcid&logoColor=white)](https://orcid.org/0000-0003-1714-6105)

**View complete publication history and citation metrics**
:::

---

## ğŸ’¼ Interested in Similar Analysis? {.section-title}

I can apply these same methodologies to your projects:

::: {.services-quick-list}
â–¸ ğŸ§¬ NGS analysis (RNA-seq, scRNA-seq, ChIP-seq, CRISPR screens)  
â–¸ ğŸ¤– Machine learning classifier development  
â–¸ ğŸ“Š Multi-omics data integration  
â–¸ ğŸ¥ Clinical trial biomarker discovery  
â–¸ ğŸ“ˆ Interactive visualization & reporting
:::

::: {.cta-center}
[ğŸ“§&nbsp;Contact Me](contact.qmd){.btn-primary-large}
[ğŸ’¼&nbsp;View Portfolio](portfolio.qmd){.btn-secondary-large}
:::